Nevro Revenue and Competitors
Estimated Revenue & Valuation
- Nevro's estimated annual revenue is currently $393.9M per year.
- Nevro received $172.5M in venture funding in June 2016.
- Nevro's estimated revenue per employee is $323,117
- Nevro's total funding is $355.8M.
- Nevro's current valuation is $3.2B. (January 2022}
- Nevro has 1219 Employees.
- Nevro grew their employee count by 10% last year.
What Is Nevro?
Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza system is the only SCS system that delivers Nevro's proprietary HF10 therapy. The Nevro® Senza® SCS system received CE Mark in 2010, TGA Approval in 2011, FDA Approval in 2015, and is commercially available in Europe, Australia, and the United States.keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals
Number of Employees
Employee Growth %
On average, analysts expect that Nevro will report full year earnings of ($2.92) per share for the current fiscal year, with EPS estimates...
Analysts expect Nevro to post earnings of ($1.11) per share for the quarter. Nevro has set its Q1 2022 guidance at EPS and its FY 2022 guidance...
Nevro Corp. NVRO is well poised for growth in the coming quarters, backed by its solid foothold in the Spinal Cord Stimulation (SCS)...
REDWOOD CITY, Calif., Nov. 1, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that provides innovative, evidence-based solutions for the treatment of chronic pain, today announced that a Delaware jury found that Nevro infringed two Boston Scientific patents (7,891, ...
REDWOOD CITY, Calif., Oct. 11, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the company will report its financial results for the third quarter ended S ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|2011-07-20||$58.0M||Undisclosed||Johnson & Johnson Development||Article|